Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Total Liabilities (2019 - 2025)

Biodesix (BDSX) has disclosed Total Liabilities for 7 consecutive years, with $89.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 17.77% year-over-year to $89.9 million, compared with a TTM value of $89.9 million through Dec 2025, up 17.77%, and an annual FY2025 reading of $89.9 million, up 17.77% over the prior year.
  • Total Liabilities was $89.9 million for Q4 2025 at Biodesix, down from $90.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $94.5 million in Q4 2023 and bottomed at $53.9 million in Q1 2022.
  • Average Total Liabilities over 5 years is $77.7 million, with a median of $76.3 million recorded in 2023.
  • The sharpest move saw Total Liabilities tumbled 68.72% in 2021, then soared 41.53% in 2023.
  • Year by year, Total Liabilities stood at $56.4 million in 2021, then increased by 28.26% to $72.3 million in 2022, then soared by 30.73% to $94.5 million in 2023, then fell by 19.2% to $76.4 million in 2024, then increased by 17.77% to $89.9 million in 2025.
  • Business Quant data shows Total Liabilities for BDSX at $89.9 million in Q4 2025, $90.4 million in Q3 2025, and $86.6 million in Q2 2025.